<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01995227</url>
  </required_header>
  <id_info>
    <org_study_id>ITL-019-HCC-VAX</org_study_id>
    <nct_id>NCT01995227</nct_id>
  </id_info>
  <brief_title>An Individualized Anti-Cancer Vaccine Study in Patients With HCC</brief_title>
  <official_title>An Individualized Anti-Cancer Vaccine (AlloVaxTM) Study in Patients With Refractory Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunovative Therapies, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunovative Therapies, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and the immunological, radiological, and
      pathological response of the personalized anti-cancer vaccine AlloVax(TM) in patients with
      refractory Hepatocellular Carcinoma (HCC) and who are not eligible for any approved HCC
      treatments or have failed all approved HCC treatments. AlloVax(TM) is a personalized
      anti-cancer vaccine combining Chaperone Rich Cell Lysate (CRCL) as a source of tumor antigen
      prepared from patient's tumor and AlloStim(TM) as an adjuvant. The combination of these two
      components provides a vaccine designed to bring out an immune response capable of finding and
      killing the tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All accrued subjects will undergo tumor harvest procedure. The tumor samples will be
      processed into personalized Chaperone Rich Cell Lysate (CRCL) vaccine. This study consists of
      three phases: priming phase, vaccination phase, and activation phase. The priming phase
      involves intradermal injections of AlloStim(TM). The aim of this phase is to increase the
      titer of Th1 immune cells in circulation. The vaccination phase involves the intradermal
      injections of AlloSim(TM) immediately followed by the intradermal injections of CRCL. This
      phase is designed to elicit tumor-specific immunity. The activation phase involves
      intravenous infusion of AlloStim(TM). This phase is designed to activate memory cells and NK
      cells and cause them to extravasate and traffic to tumor sites.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study site change
  </why_stopped>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>30 days</time_frame>
    <description>To assess adverse events and laboratory abnormalities associated with AlloVax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor-Specific Immunity</measure>
    <time_frame>30 days</time_frame>
    <description>Determine if AlloVax elicits detectable tumor specific immunity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Biomarker Status</measure>
    <time_frame>30 days</time_frame>
    <description>Biomarker concentration will be evaluated at different time points.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anti-Tumor Response</measure>
    <time_frame>30 days</time_frame>
    <description>To determine if there are any evidence of anti-tumor immune-mediated response by radiological and pathological changes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>approximately 12 months</time_frame>
    <description>Baseline to date of death from any cause</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>AlloVax Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal injection (ID) of AlloStim(TM) (1ml) on day 4 and 7. AlloVax Treatment: ID injection of AlloSim(TM) (1 ml) followed immediately by the ID injection of CRCL (1ml) on day 11 and 14 in same location on the left arm and on day 18 and 21 in the same location on the right arm. Intravenous infusion of AlloStim(TM)(5ml) and a CRCL alone Intradermal injection on Day 27.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloVax</intervention_name>
    <description>Personalized anti-cancer vaccine</description>
    <arm_group_label>AlloVax Treatment</arm_group_label>
    <other_name>AlloStim plus CRCL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CRCL</intervention_name>
    <description>Personalized anti-cancer vaccine</description>
    <arm_group_label>AlloVax Treatment</arm_group_label>
    <other_name>Chaperone Rich Cell Lysate</other_name>
    <other_name>AlloVax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim</intervention_name>
    <description>ID injections IV infusion</description>
    <arm_group_label>AlloVax Treatment</arm_group_label>
    <other_name>AlloStim ID</other_name>
    <other_name>AlloStim IV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any Patients with a diagnosis of HCC based on histology or the current accepted
             radiological measures.

          -  Age &gt; 18 years.

          -  Patient has an MRI or CT result (positive for HCC) up to 3 months prior to
             recruitment.

          -  AFP &gt; 30.

          -  Patient who is not eligible or failed all approved HCC treatments.

        Exclusion Criteria:

          -  Patient is unable or unwilling to sign informed consent.

          -  Patients that are participating in other clinical trials evaluating experimental
             treatments or procedures.

          -  Severe congestive heart failure (LVEF on echocardiogram &lt; 20%).

          -  Severe pulmonary hypertension (By echocardiogram, PAS &gt;45 mmHg).

          -  Uncontrolled diabetes mellitus (HBA1C &gt;9.5%).

          -  Any autoimmune disorder, which is currently being treated with prednisone or any other
             immune suppressive medication.

          -  Patients currently receiving total parenteral nutrition if they have contraindications
             to oral drugs.

          -  Patients with positive HIV1, HIV2, HTLV1, HTLV2, and RPR (syphilis).

          -  Women who are pregnant or breast feeding.

          -  Patients, based on the opinion of the investigator, should not be enrolled into this
             study.

          -  HBV DNA positive.

          -  If the patient is HBsAg positive or HBcAB positive, but HBV DNA negative, irrespective
             of his/her anti-HBS status, patient can be enrolled, but will receive preemptive
             therapy with Lamivudine.

          -  Patients with HBV DNA positive will not be enroll, but if turned negative with therapy
             can be enrolled. Patients with HBV and HCV will be followed by HBV DNA and HCV RNA
             levels during the trial.

          -  Any metastasis except for portal vein involvement.

          -  Patients with Child Pugh above B8.

          -  Prior experimental therapy or cancer vaccine treatment (e.g., dendritic cell therapy,
             heat shock vaccine).

          -  History of blood transfusion reactions.

          -  Known allergy to bovine or murine products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaron Ilan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hadassah Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hebrew University-Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/livercancer.html</url>
    <description>Liver Cancer</description>
  </link>
  <results_reference>
    <citation>Epple LM, Bemis LT, Cavanaugh RP, Skope A, Mayer-Sonnenfeld T, Frank C, Olver CS, Lencioni AM, Dusto NL, Tal A, Har-Noy M, Lillehei KO, Katsanis E, Graner MW. Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine. Int J Hyperthermia. 2013 Aug;29(5):390-8. doi: 10.3109/02656736.2013.800997. Epub 2013 Jun 20.</citation>
    <PMID>23786302</PMID>
  </results_reference>
  <results_reference>
    <citation>Mayer-Sonnenfeld T, Har-Noy M, Lillehei KO, Graner MW. Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome leads to unique structure. Int J Hyperthermia. 2013 Sep;29(6):520-7. doi: 10.3109/02656736.2013.796529. Epub 2013 Jun 4.</citation>
    <PMID>23734882</PMID>
  </results_reference>
  <results_reference>
    <citation>LaCasse CJ, Janikashvili N, Larmonier CB, Alizadeh D, Hanke N, Kartchner J, Situ E, Centuori S, Har-Noy M, Bonnotte B, Katsanis E, Larmonier N. Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-Î³-dependent mechanism. J Immunol. 2011 Dec 15;187(12):6310-7. doi: 10.4049/jimmunol.1101812. Epub 2011 Nov 9.</citation>
    <PMID>22075702</PMID>
  </results_reference>
  <results_reference>
    <citation>Janikashvili N, LaCasse CJ, Larmonier C, Trad M, Herrell A, Bustamante S, Bonnotte B, Har-Noy M, Larmonier N, Katsanis E. Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. Blood. 2011 Feb 3;117(5):1555-64. doi: 10.1182/blood-2010-06-288621. Epub 2010 Dec 1.</citation>
    <PMID>21123824</PMID>
  </results_reference>
  <results_reference>
    <citation>Har-Noy M, Zeira M, Weiss L, Fingerut E, Or R, Slavin S. Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma. Leuk Res. 2009 Apr;33(4):525-38. doi: 10.1016/j.leukres.2008.08.017. Epub 2008 Oct 1.</citation>
    <PMID>18834631</PMID>
  </results_reference>
  <results_reference>
    <citation>Har-Noy M, Zeira M, Weiss L, Slavin S. Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity. Leuk Res. 2008 Dec;32(12):1903-13. doi: 10.1016/j.leukres.2008.05.007. Epub 2008 Jun 18.</citation>
    <PMID>18565579</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2013</study_first_posted>
  <last_update_submitted>April 1, 2015</last_update_submitted>
  <last_update_submitted_qc>April 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver cancer</keyword>
  <keyword>HCC</keyword>
  <keyword>tumor vaccine</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>personalized anti-cancer vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

